Key Takeaways JNJ stock stayed above 50- and 200-day SMAs for 8 months, signaling sustained bullish momentum.J&'s growth is driven by Innovative Medicine strength, new drugs, and R&D and M&A spend.JNJ faces Stelara patent loss, China headwinds, and 74,000 talc lawsuits, impacting future outlook.Johnson & Johnson’s (JNJ) stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor confidence. Notab ...

Tilly's, Inc. (TLYS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TLYS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically ...

Time now for Options Corner here to take us through a look at the chart and an example trade. We've got Tom White, senior options contributor and co-host of Fast Market. All right, Tom, this has had a monster run this year.Take us through what you notice on this chart. >> Yeah, uncertainty in the energy markets. Definitely uh helping out uh the stock here today.Um if you look at it, it was relatively muted over the last year. Here we got a one-year oneed one day chart uh here and I wanted to cut put a coupl ...

Core Insights - Amgen (AMGN) stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January, indicating a strong upward trend supported by positive earnings and a favorable outlook for 2026 [1][2][8] Financial Performance - Amgen's revenues rose 10% to $36.8 billion in 2025, driven by increasing patient demand for its innovative medicines [5] - Fourteen of Amgen's products now generate over $1 billion in annual sales, reducing reliance on any single product [6] Key Products and Pipeline - Key drugs such as Repatha, Evenity, Uplizna, and new drugs like Tavneos and Tezspire are contributing to revenue growth, while new biosimilars are also enhancing top-line performance [6][12] - Amgen is developing MariTide, an obesity treatment, which differentiates itself from competitors by offering less frequent dosing [10] - Ongoing clinical studies for MariTide are expected to yield important data over the next six to twelve months, potentially acting as catalysts for stock performance [11] Biosimilars and Market Position - Amgen's biosimilars generated approximately $3 billion in sales in 2025, marking a 37% year-over-year increase, and have contributed over $13 billion in sales since their first launch in 2018 [12] - New biosimilar launches are crucial for mitigating the impact of Amgen's loss of exclusivity over the next few years [13] Challenges and Headwinds - Patents for key drugs Prolia and Xgeva expired in February 2025 in the U.S., leading to expected significant revenue declines in 2026 due to the launch of several biosimilars [14] - Pricing pressures and competitive challenges are affecting sales of several products, including Otezla and Lumakras [16][17] - Recent setbacks in drug approvals, such as the withdrawal of Tavneos and the decision not to seek approval for bemarituzumab, have raised concerns [18][19] Valuation and Estimates - Amgen's shares have increased by 11.6% over the past year, outperforming the industry average of 8.0% [20] - The stock is currently trading at a price/earnings ratio of 15.67, which is lower than the industry average of 17.25, although it is above its five-year mean of 13.81 [20] - Consensus estimates for earnings have risen for 2026 from $21.71 to $22.22 per share, and for 2027 from $22.30 to $23.24 per share [23] Long-term Outlook - Amgen is well-positioned for long-term revenue growth, with expectations that key drugs and biosimilars will drive top-line growth in 2026, partially offsetting the impact of biosimilar erosion and pricing declines [27]

Core Viewpoint - Garmin Ltd. (GRMN) is showing potential for a bullish breakout due to a recent "golden cross" in its moving averages, indicating a key technical support level has been reached [1] Technical Analysis - GRMN's 50-day simple moving average has crossed above its 200-day simple moving average, a pattern known as a "golden cross," which is typically associated with bullish market sentiment [1] - The golden cross pattern consists of three stages: a downtrend that bottoms out, a crossover of the shorter moving average above the longer one, and continued upward momentum in stock prices [2] Performance Metrics - Over the past four weeks, GRMN has experienced a rally of 9.4%, and it currently holds a 1 (Strong Buy) rating on the Zacks Rank, suggesting a strong potential for further gains [3] - Earnings expectations for GRMN are positive, with four upward revisions in estimates for the current quarter and no downward revisions over the past 60 days, indicating growing investor confidence [3] Investment Outlook - Given the technical indicators and positive earnings estimate revisions, GRMN is positioned for potential gains in the near future [4]

🚨 BULLISH: $BNB HITS $672 AS GOLDEN CROSS PATTERN EMERGES$BNB is flashing a textbook bullish signal as the 50-day SMA crosses above the 200-day SMA, forming a golden cross amid broader altcoin momentum.On-chain metrics are turning positive as BNB Chain ecosystem activity picks up. With deflationary token burns continuing to reduce supply and the broader crypto market pushing upward, technicals and fundamentals are aligning, analysts eye $800-$900 as the next key resistance zone. ...

Core Viewpoint - AMN Healthcare Services Inc (AMN) is showing potential for bullish movement due to a recent technical indicator known as a "golden cross," which suggests a possible breakout for investors [1]. Technical Analysis - AMN's 50-day simple moving average has recently crossed above its 200-day moving average, indicating a bullish signal [1]. - A golden cross typically follows a downtrend, where the shorter moving average crosses above the longer one, leading to a positive trend reversal [2]. Performance Metrics - AMN's stock has increased by 19.2% over the last four weeks, suggesting strong upward momentum [3]. - The company currently holds a 3 (Hold) rating on the Zacks Rank, indicating a neutral outlook [3]. Earnings Expectations - There have been three upward revisions in earnings expectations for the current quarter, with no downward changes in the past 60 days, which supports the bullish sentiment [3]. - The Zacks Consensus Estimate for AMN has also increased, further reinforcing the positive outlook for the company [4].

Core Viewpoint - Leonardo DRS, Inc. is showing potential for a bullish breakout due to a recent technical indicator known as a "golden cross" [1] Technical Analysis - DRS's 50-day simple moving average has crossed above its 200-day simple moving average, indicating a potential bullish trend [1] - A golden cross typically signifies a reversal from a downtrend to an upward trend, consisting of three stages: a downtrend, the crossover of moving averages, and an upward price movement [2] Performance Metrics - DRS has experienced a rally of 17.4% over the past four weeks, suggesting positive momentum [3] - The company currently holds a 3 (Hold) rating on the Zacks Rank, indicating a potential for further gains [3] Earnings Outlook - There have been no cuts to earnings estimates for the current quarter, with two revisions higher in the past 60 days, which supports a positive earnings outlook [3] - The Zacks Consensus Estimate for DRS has also increased, reinforcing the bullish sentiment [3] Investment Consideration - The combination of positive earnings estimate revisions and the technical breakout suggests that investors should monitor DRS for potential gains in the near future [4]

Core Viewpoint - Alector, Inc. (ALEC) shows potential as a stock pick due to a recent "golden cross" event, indicating a bullish trend reversal [1][4]. Technical Analysis - A golden cross occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), suggesting a potential bullish breakout [2]. - The formation of a golden cross typically follows three stages: a downtrend, the crossover of moving averages, and an upward price movement [3]. Recent Performance - ALEC has increased by 11.7% over the last four weeks, indicating positive momentum [4]. - The company currently holds a 3 (Hold) rating on the Zacks Rank, reflecting a neutral outlook [4]. Earnings Outlook - There have been no cuts to earnings estimates for the current quarter, with four revisions upward in the past 60 days, contributing to a positive earnings outlook [4]. - The Zacks Consensus Estimate for ALEC has also seen an increase, further supporting the bullish case for the stock [5].

Core Viewpoint - Gaming and Leisure Properties, Inc. (GLPI) has reached a significant support level and is considered a potential investment opportunity due to a recent technical indicator known as a "golden cross" [1] Technical Analysis - GLPI's 50-day simple moving average has recently broken above its 200-day moving average, indicating a bullish breakout may be on the horizon [1] - A golden cross typically involves a downtrend followed by a crossover of the shorter moving average over the longer moving average, leading to a positive trend reversal [2] Performance Metrics - Over the past four weeks, GLPI has rallied by 9.5%, and it currently holds a 2 (Buy) rating on the Zacks Rank, suggesting potential for further gains [3] - There has been one upward revision in earnings estimates for GLPI in the last 60 days, with no downward revisions, indicating a positive earnings outlook for the current quarter [3] Investment Outlook - Given the positive technical indicators and the upward movement in earnings estimates, GLPI may present a favorable opportunity for investors looking for gains in the near future [4]